S&P 500   3,297.19 (+0.80%)
DOW   26,631.20 (+0.77%)
QQQ   269.04 (+1.22%)
AAPL   443.48 (+4.34%)
MSFT   212.53 (+3.67%)
FB   252.12 (-0.61%)
GOOGL   1,481.21 (-0.45%)
AMZN   3,127.30 (-1.18%)
NVDA   434.60 (+2.36%)
CGC   18.36 (+0.44%)
BABA   260.36 (+3.72%)
TSLA   1,474.04 (+3.02%)
MU   50.18 (+0.24%)
GE   6.02 (-0.82%)
AMD   77.95 (+0.66%)
T   29.48 (-0.34%)
F   6.58 (-0.45%)
ACB   9.79 (-3.93%)
GILD   70.50 (+1.40%)
NFLX   495.59 (+1.37%)
DIS   116.41 (-0.45%)
BAC   25.00 (+0.48%)
BA   154.22 (-2.39%)
S&P 500   3,297.19 (+0.80%)
DOW   26,631.20 (+0.77%)
QQQ   269.04 (+1.22%)
AAPL   443.48 (+4.34%)
MSFT   212.53 (+3.67%)
FB   252.12 (-0.61%)
GOOGL   1,481.21 (-0.45%)
AMZN   3,127.30 (-1.18%)
NVDA   434.60 (+2.36%)
CGC   18.36 (+0.44%)
BABA   260.36 (+3.72%)
TSLA   1,474.04 (+3.02%)
MU   50.18 (+0.24%)
GE   6.02 (-0.82%)
AMD   77.95 (+0.66%)
T   29.48 (-0.34%)
F   6.58 (-0.45%)
ACB   9.79 (-3.93%)
GILD   70.50 (+1.40%)
NFLX   495.59 (+1.37%)
DIS   116.41 (-0.45%)
BAC   25.00 (+0.48%)
BA   154.22 (-2.39%)
S&P 500   3,297.19 (+0.80%)
DOW   26,631.20 (+0.77%)
QQQ   269.04 (+1.22%)
AAPL   443.48 (+4.34%)
MSFT   212.53 (+3.67%)
FB   252.12 (-0.61%)
GOOGL   1,481.21 (-0.45%)
AMZN   3,127.30 (-1.18%)
NVDA   434.60 (+2.36%)
CGC   18.36 (+0.44%)
BABA   260.36 (+3.72%)
TSLA   1,474.04 (+3.02%)
MU   50.18 (+0.24%)
GE   6.02 (-0.82%)
AMD   77.95 (+0.66%)
T   29.48 (-0.34%)
F   6.58 (-0.45%)
ACB   9.79 (-3.93%)
GILD   70.50 (+1.40%)
NFLX   495.59 (+1.37%)
DIS   116.41 (-0.45%)
BAC   25.00 (+0.48%)
BA   154.22 (-2.39%)
S&P 500   3,297.19 (+0.80%)
DOW   26,631.20 (+0.77%)
QQQ   269.04 (+1.22%)
AAPL   443.48 (+4.34%)
MSFT   212.53 (+3.67%)
FB   252.12 (-0.61%)
GOOGL   1,481.21 (-0.45%)
AMZN   3,127.30 (-1.18%)
NVDA   434.60 (+2.36%)
CGC   18.36 (+0.44%)
BABA   260.36 (+3.72%)
TSLA   1,474.04 (+3.02%)
MU   50.18 (+0.24%)
GE   6.02 (-0.82%)
AMD   77.95 (+0.66%)
T   29.48 (-0.34%)
F   6.58 (-0.45%)
ACB   9.79 (-3.93%)
GILD   70.50 (+1.40%)
NFLX   495.59 (+1.37%)
DIS   116.41 (-0.45%)
BAC   25.00 (+0.48%)
BA   154.22 (-2.39%)
Log in

LON:C4XDC4X Discovery Share Price, Forecast & News

GBX 18.50
+0.75 (+4.23 %)
(As of 07/14/2020)
Add
Compare
Today's Range
17.71
Now: GBX 18.50
19.70
50-Day Range
13.50
MA: GBX 15.18
18.75
52-Week Range
0.14
Now: GBX 18.50
47.44
Volume267,415 shs
Average Volume2,983 shs
Market Capitalization£22.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom. The company has a suite of proprietary technologies across the drug discovery process, including Taxonomy 3, a novel in silico platform technology that utilises proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behaviour and physical properties of drug molecules; and MolPlex. Its product pipeline comprises Oral Orexin-1, an antagonist for the treatment of addiction; Oral GPR142 and GLP-1, an agonist for the treatment of type 2 diabetes; Oral Nrf-2 activators and IL-17 inhibitors for the treatment of inflammatory disorders; and various products for the treatment of oncology. The company has collaboration agreement with the University of Bristol, the University of Reading, the University of Oxford, and the University of Manchester; and a discovery partnership with Horizon Discovery Group plc to develop synthetic lethality targets in oncology. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was founded in 2007 and is based in Manchester, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.62 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-161-2355085

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£7.06 million
Cash FlowGBX 6.99 per share
Book ValueGBX 9.50 per share

Profitability

Miscellaneous

Employees47
Market Cap£22.05 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 18.50
+0.75 (+4.23 %)
(As of 07/14/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive C4XD News and Ratings via Email

Sign-up to receive the latest news and ratings for C4XD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











C4X Discovery (LON:C4XD) Frequently Asked Questions

How has C4X Discovery's stock been impacted by COVID-19 (Coronavirus)?

C4X Discovery's stock was trading at GBX 9.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, C4XD shares have increased by 89.7% and is now trading at GBX 18.50.
View which stocks have been most impacted by Coronavirus
.

How were C4X Discovery's earnings last quarter?

C4X Discovery Holdings PLC (LON:C4XD) posted its quarterly earnings results on Wednesday, April, 29th. The company reported ($5.02) earnings per share for the quarter, beating the consensus estimate of ($5.50) by $0.48.
View C4X Discovery's earnings history
.

Has C4X Discovery been receiving favorable news coverage?

Media headlines about C4XD stock have been trending negative on Monday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. C4X Discovery earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next several days.
View the latest news about C4X Discovery
.

Who are some of C4X Discovery's key competitors?

What other stocks do shareholders of C4X Discovery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other C4X Discovery investors own include Rio Tinto (RIO), Ryder System (R), Pearson (PSON), Moss Bros Group (MOSB), Inditex (ITX), Inland Homes (INL), Fundsmith Emerging Equities Trust (FEET), easyJet (EZJ), Card Factory (CARD) and Berkeley Group (BKG).

Who are C4X Discovery's key executives?

C4X Discovery's management team includes the following people:
  • Dr. Clive James Dix, CEO & Director (Age 64)
  • Mr. Bradley Richard Hoy, CFO & Director (Age 56)
  • Dr. Justian Craig Fox, Chief Scientific Officer & Director (Age 44)
  • Ms. Bhavna Hunjan, Head of Corp. Strategy & Devel.
  • Mr. Mark James Sullivan, Company Sec.

What is C4X Discovery's stock symbol?

C4X Discovery trades on the London Stock Exchange (LON) under the ticker symbol "C4XD."

How do I buy shares of C4X Discovery?

Shares of C4XD and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is C4X Discovery's stock price today?

One share of C4XD stock can currently be purchased for approximately GBX 18.50.

How big of a company is C4X Discovery?

C4X Discovery has a market capitalization of £22.05 million and generates £7.06 million in revenue each year. C4X Discovery employs 47 workers across the globe.

What is C4X Discovery's official website?

The official website for C4X Discovery is www.c4xdiscovery.com.

How can I contact C4X Discovery?

C4X Discovery's mailing address is 53 Portland Street, MANCHESTER, M1 3LD, United Kingdom. The company can be reached via phone at +44-161-2355085.

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.